FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Circulating tumor DNA status and dynamics predict recurrence in patients with resected extrahepatic cholangiocarcinoma. PMID 39532185 · J Hepatol · 2025-May 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Long-term efficacy and safety of stapokibart for moderate-to-severe atopic dermatitis: 52-week results from a phase 3 trial. PMID 39450683 · Allergy · 2025-May 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Upadacitinib for Perianal Fistulizing Crohn's Disease: A Post Hoc Analysis of 3 Phase 3 Trials. PMID 39326583 · Clin Gastroenterol Hepatol · 2025-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Impact of empagliflozin on cardiac structure and function assessed by echocardiography after myocardial infarction: a post-hoc sub-analysis of the emmy trial. PMID 39297940 · Clin Res Cardiol · 2025-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Abdominal Noncontrast Computed Tomography Scanning to Screen for Kidney Cancer and Other Abdominal Pathology Within Community-based Computed Tomography Screening for Lung Cancer: Results of the Yorkshire Kidney Screening Trial. PMID 39271419 · Eur Urol · 2025-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Safety, efficacy, and pharmacokinetics of oral testosterone undecanoate in males with hypogonadism. PMID 39252657 · Andrology · 2025-May 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Evaluation of early treatment with intravenous idursulfase and intrathecal idursulfase-IT on cognitive function in siblings with neuronopathic mucopolysaccharidosis II. PMID 39252529 · J Inherit Metab Dis · 2025-May 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Design of a Phase 3, Global, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn. PMID 39197469 · Am J Perinatol · 2025-May 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of topical minocycline foam (FMX101 4%) in treatment of Chinese subjects with moderate-to-severe facial acne vulgaris: A phase 3, multi-centre, randomized, double-blind, vehicle-controlled study. PMID 38948962 · J Eur Acad Dermatol Venereol · 2025-May 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Mortality impact, risks, and benefits of general population screening for ovarian cancer: the UKCTOCS randomised controlled trial. PMID 37183782 · Health Technol Assess · 2025-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Within-trial cost-effectiveness of novel macrophage-regulating treatment on wound healing in patients with diabetic foot ulcers. PMID 40202410 · J Food Drug Anal · 2025-Mar-31 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Inhaled sedation versus propofol in respiratory failure in the ICU (INSPiRE-ICU2): study protocol for a multicenter randomized controlled trial. PMID 40165305 · Trials · 2025-Mar-31 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Prognostic impact of clinical trial eligibility in patients with advanced gastric cancer. PMID 40164709 · Sci Rep · 2025-Mar-31 The record describes a retrospective prognostic study analyzing the impact of eligibility criteria from the CheckMate 649 trial on outcomes in clinical practice. It is not the original trial report with primary or secondary efficacy results. Therefore, it is excluded. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Whole stomach versus narrow gastric tube reconstruction after esophagectomy for esophageal cancer (ATHLETE trial): study protocol for a randomized controlled trial. PMID 40155976 · Trials · 2025-Mar-29 方案论文未报告临床试验结果。 |
H
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine targeting serogroups A, C, W, Y, and X when co-administered with routine childhood vaccines at ages 9 months and 15 months in Mali: a single-centre, double-blind, randomised, controlled, phase 3, non-inferiority trial. PMID 40086461 · Lancet · 2025-Mar-29 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Combining Cutting and Drug-eluting Balloon for Resistant Arteriovenous Fistula Stenosis (CONCERTO)-A Pilot Study. PMID 40384896 · Interv Radiol (Higashimatsuyama) · 2025-Mar-28 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Dronedarone provides effective early rhythm control: post-hoc analysis of the ATHENA trial using EAST-AFNET 4 criteria. PMID 40295782 · Europace · 2025-Mar-28 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Prospective, Randomized, Comparative Study of Myeloablative Fludarabine/Busulfan and Fludarabine/Busulfan/Total Body Irradiation Conditioning in Myeloid Diseases. PMID 40227676 · Cancers (Basel) · 2025-Mar-28 Phase is not explicitly confirmed as Phase III/IIIb or Phase II/III; the study is a prospective randomized trial comparing two drug-containing conditioning regimens (fludarabine/busulfan with or without TBI) for myeloid malignancies, reporting OS and relapse as time-to-event endpoints. However, the phase is not stated in the metadata, and the deterministic review flagged phase evidence as unclear, leading to exclusion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| PD-1 inhibitors improve the efficacy of transcatheter arterial chemoembolization combined with apatinib in advanced hepatocellular carcinoma: a meta-analysis and trial sequential analysis. PMID 40155828 · BMC Cancer · 2025-Mar-28 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| The Effect of Nurse Navigators in Digital Remote Monitoring in Cancer Care: Case Study Using Structural Equation Modeling. PMID 40153795 · J Med Internet Res · 2025-Mar-28 The record describes a Phase III RCT, but the primary endpoint is 'relative dose intensity', not a time-to-event efficacy endpoint. The outcomes analyzed (toxicity, hospitalization, etc.) are not time-to-event efficacy metrics, and no Kaplan-Meier or HR data is reported. Therefore, it does not meet the required time-to-event efficacy endpoint criterion. |
H
L
B
|
旧查询独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Flecainide acetate inhalation solution for cardioversion of recent-onset, symptomatic atrial fibrillation: results of the phase 3 RESTORE-1 trial. PMID 40132102 · Europace · 2025-Mar-28 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| A Missing Mechanism of Effect: How People Who Habitually Replot Stories React Differently (Or Not so Differently) to Melanoma Narratives. PMID 39550610 · J Health Commun · 2025-Mar-28 While the study is an oncology-related randomized trial in humans, it is excluded because it is not a drug intervention trial and does not have a primary time-to-event efficacy endpoint. The outcome measured is behavioral intention, not survival or progression metrics. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| NeoTRACK trial: Neoadjuvant TiRagolumab, Atezolizumab and Chemotherapy - dissection of IO- efficacy in NSCLC by longitudinal tracKing - protocol of a non-randomised, open-label, single-arm, phase II study. PMID 40147985 · BMJ Open · 2025-Mar-27 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Association of energy source with outcomes in en bloc TURB: secondary analysis of a randomized trial. PMID 40146341 · World J Urol · 2025-Mar-27 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal Polyps. PMID 40106374 · N Engl J Med · 2025-Mar-27 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Inebilizumab for Treatment of IgG4-Related Disease. PMID 39541094 · N Engl J Med · 2025-Mar-27 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Clinical experience with cryopreserved mesenchymal stem cells for cardiovascular applications: A systematic review. PMID 40160690 · World J Stem Cells · 2025-Mar-26 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Immunomodulatory gene networks predict treatment response and survival to de-escalated, anthracycline-free neoadjuvant chemotherapy in triple-negative breast cancer in the WSG-ADAPT-TN trial. PMID 40140821 · Mol Cancer · 2025-Mar-26 The record describes a randomized trial in oncology with a drug intervention and a time-to-event endpoint (iDFS), but the trial phase is not specified in the provided metadata as Phase III/IIIb or Phase II/III. Furthermore, the primary endpoint is pCR (a binary endpoint), while iDFS is a secondary endpoint. To be eligible, the trial must be Phase III/IIIb or Phase II/III and must have a primary/key secondary time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Systemic immunomodulation by irreversible electroporation versus stereotactic ablative body radiotherapy in locally advanced pancreatic cancer: the CROSSFIRE trial. PMID 40139834 · J Immunother Cancer · 2025-Mar-26 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with and without Advanced CKD: Systematic Review and Meta-Analysis. PMID 40137838 · Clin J Am Soc Nephrol · 2025-Mar-26 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Positron emission tomography-adapted therapy for first-line treatment in adults with Hodgkin lymphoma. PMID 40135712 · Cochrane Database Syst Rev · 2025-Mar-26 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized study. PMID 40010134 · Eur J Cancer · 2025-Mar-26 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Post-recurrence survival in patients with stage III gastric cancer who received adjuvant chemotherapy; post-hoc analysis of the JACCRO GC-07 study. PMID 39999670 · Eur J Cancer · 2025-Mar-26 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| ChemoID-guided therapy improves objective response rate in recurrent platinum-resistant ovarian cancer randomized clinical trial. PMID 40133484 · NPJ Precis Oncol · 2025-Mar-25 The study is a randomized clinical trial in oncology (ovarian cancer) with a drug intervention (chemotherapy) and reports time-to-event endpoints (PFS with HR). However, the abstract explicitly states the primary outcome was Objective Response Rate (ORR), which is not a time-to-event endpoint. The phase (III/IIIb or II/III) is not clearly established in the provided metadata. Therefore, it does not meet all required criteria for inclusion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Treatment group-specific inferences in Phase III Randomized Oncology Trials. PMID 40126209 · Acta Oncol · 2025-Mar-24 This is a methodological review analyzing 774 published Phase III oncology trials, not the original result report of a single randomized trial. It lacks a specific drug intervention and does not present a primary time-to-event efficacy endpoint for a single study. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Impact of Cholecalciferol Supplementation on Radiotherapy Outcomes in Advanced Cervical Cancer. PMID 40123110 · Med Sci Monit · 2025-Mar-24 The study is a randomized, oncology, human trial with a drug intervention (cholecalciferol). However, it is not a Phase III trial, and the primary outcome is a categorical response rate (complete response), not a time-to-event endpoint (OS, PFS, DFS, etc.) with Kaplan-Meier or HR analysis. Therefore, it does not meet the eligibility criteria for a KM-digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of a Newly Developed Botulinum Toxin A (MBA-P01) in Patients with Moderate-to-Severe Glabellar Lines: A Randomized, Double-Blind, Active-Controlled, Multi-Center, Phase III Study with a Subgroup Analysis on Patients with COVID-19. PMID 40278658 · Toxins (Basel) · 2025-Mar-23 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Ulinastatin in the treatment of radiotherapy-induced oral mucositis in locoregionally advanced nasopharyngeal carcinoma: a phase 3 randomized clinical trial. PMID 40122906 · Nat Commun · 2025-Mar-23 The study is a Phase III randomized trial in oncology with time-to-event endpoints, but it fails the core criterion of having a drug-containing intervention as the primary efficacy focus. The drug (ulinastatin) is used to prevent/treat a toxicity (oral mucositis) of radiotherapy, not as an anti-cancer therapy. The primary endpoint is a toxicity/incidence endpoint, not a time-to-event efficacy endpoint. The reported survival outcomes are secondary and show no significant difference, indicating the drug is not being evaluated for its anti-tumor efficacy. Therefore, it does not meet the requirement for a drug intervention trial with a primary/key secondary time-to-event efficacy endpoint. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Assessing the impact of a self-guided digital intervention for fear of cancer recurrence (iConquerFear) in ovarian cancer survivors: a pilot randomised waitlist-controlled trial. PMID 40122804 · BMC Cancer · 2025-Mar-23 The record describes a pilot randomized trial of a digital intervention for fear of cancer recurrence. It is not Phase III/IIIb or Phase II/III, lacks a drug intervention, and does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS). Therefore, it is not eligible. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A Phase 3 Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Vaccine, Compared with PPSV23, in Adults ≥50 Years of Age (STRIDE-10). PMID 40333240 · Vaccines (Basel) · 2025-Mar-22 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Exploring the impact of metabolic comorbidities on epicardial adipose tissue in heart failure with preserved ejection fraction. PMID 40121452 · Cardiovasc Diabetol · 2025-Mar-22 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Serum VEGF-A as a biomarker for the addition of bevacizumab to chemo-immunotherapy in metastatic NSCLC. PMID 40121197 · Nat Commun · 2025-Mar-22 The report is a preplanned biomarker subgroup analysis of a phase 3 randomized trial, not the primary formal-result report of the trial's overall efficacy. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Pharmacological Monotherapy for Depressive Disorders: Current and Future-A Narrative Review. PMID 40282849 · Medicina (Kaunas) · 2025-Mar-21 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| The Pharmacologic Inhibition of KRAS Mutants as a Treatment for Cancer: Therapeutic Principles and Clinical Results. PMID 40009739 · Dtsch Arztebl Int · 2025-Mar-21 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II Study. PMID 39889250 · J Clin Oncol · 2025-Mar-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Recurrent Small Hepatocellular Carcinoma: A Randomized, Open-Label, Controlled Trial. PMID 39693584 · J Clin Oncol · 2025-Mar-20 The report is a Phase III randomized oncology trial with a time-to-event efficacy endpoint, but it does not involve a drug-containing intervention, comparing only non-drug local therapies. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1). PMID 39680823 · J Clin Oncol · 2025-Mar-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Randomized, Phase III Trial of Mixed Formulation of Fosrolapitant and Palonosetron (HR20013) in Preventing Cisplatin-Based Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: PROFIT. PMID 39621965 · J Clin Oncol · 2025-Mar-20 The study is a randomized Phase III trial with a drug intervention and reports original results. However, the primary and key secondary endpoints are proportions (complete response rates), not time-to-event outcomes (OS, PFS, DFS, etc.). Therefore, it does not meet the requirement for a primary/key secondary time-to-event efficacy endpoint. |
H
L
B
|
旧查询独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Non-invasive physical plasma for preventing radiation dermatitis in breast cancer: study protocol for a phase 3 randomised double-blind placebo-controlled trial (NIPP-RD III). PMID 40108640 · Trials · 2025-Mar-19 方案论文未报告临床试验结果。 |
H
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Evaluation of the androgen receptor in patients with ERα-positive early breast cancer treated with adjuvant tamoxifen ± fluoxymesterone. PMID 40108635 · Breast Cancer Res · 2025-Mar-19 This report is a biomarker subgroup analysis of a randomized trial, not the primary result report of a definitive Phase III/IIIb or Phase II/III trial. The trial phase is not explicitly established in the provided metadata as meeting the required threshold. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |